OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press47610.17650/1818-8346-2021-16-2-70-80SUPPORTIVE THERAPY ASPECTSАСПЕКТЫ ПОДДЕРЖИВАЮЩЕЙ ТЕРАПИИVaccination against SARS-COV‑2 in oncologyВакцинация против SARS-COV‑2 в онкологической практикеhttps://orcid.org/0000-0003-4117-0041PolyakovA. A.ПоляковА. А.
Russian Federation

32nd Botkinskiy Proezd, Moscow 125284

125284 Москва, 2‑й Боткинский проезд, 3

LuninV. V.ЛунинВ. В.
Russian Federation

32nd Botkinskiy Proezd, Moscow 125284

125284 Москва, 2‑й Боткинский проезд, 3

AbbaysbeyliF. M.АббайсбейлиФ. М.
Russian Federation

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

8 Trubetskaya St., Moscow 119991

143081 Московская обл., д. Лапино, 1‑е Успенское шоссе, 111

119991 Москва, ул. Трубецкая, 8

TimofeevaO. L.ТимофееваО. Л.
Russian Federation

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

8 Trubetskaya St., Moscow 119991

143081 Московская обл., д. Лапино, 1‑е Успенское шоссе, 111

119991 Москва, ул. Трубецкая, 8

https://orcid.org/0000-0002-4614-606XLarionovaV. B.ЛарионоваВ. Б.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

115478 Москва, Каширское шоссе, 24

https://orcid.org/0000-0003-1564-424XZeynalovaP. A.ЗейналоваП. А.
Russian Federation

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

8 Trubetskaya St., Moscow 119991

143081 Московская обл., д. Лапино, 1‑е Успенское шоссе, 111

119991 Москва, ул. Трубецкая, 8

https://orcid.org/0000-0003-4927-5585FedenkoA. A.ФеденкоА. А.
Russian Federation

Aleksandr Aleksandrovich Fedenko

32nd Botkinskiy Proezd, Moscow 125284

Александр Александрович Феденко

125284 Москва, 2‑й Боткинский проезд, 3

fedenko@eesg.ruP.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Center, Ministry of Health of RussiaМосковский научно-исследовательский онкологический институт им. П.А. Герцена - филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава РоссииClinical Hospital “Lapino” of the “Mother and Child” Group of companiesКлинический госпиталь «Лапино» группы компаний «Мать и дитя»I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaФГАОУ ВО Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет) Минздрава РоссииN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России0706202116270800406202104062021https://oncohematology.abvpress.ru/ongm/article/view/476

The objective of the study a detailed, systematic review of the world literature data, which includes all aspects of recommendations for vaccination against SARS-COV‑2 in cancer patients.

Materials and methods. Information search was carried out in PubMed, MedLine, Scopus, Web of Science, RSCI.

The work included data from literature and information sources that were published before February 2021.

Results. The data of retrospective and prospective clinical studies are analyzed. This paper reflects considerations and recommendations for the vaccination of cancer patients by Russian and foreign specialists in the context of COVID‑19 pandemic. The review presents current recommendations for vaccination against SARS-COV‑2 in patients with solid tumors, hematological malignancies, recipients of hematopoietic stem cells and cell therapy.

Conclusion. To date, groups at increased risk of infection with the new coronavirus have been identified. These groups include patients with cancer. The presence of tumor does not allow a delay in start of therapy, and requires careful monitoring and observation. In this regard, despite the pandemic, the treatment of cancer patients must be continued regardless of the circumstances. Cancer patients should not be deprived of the opportunity to be vaccinated against SARS-COV‑2. Every patient should be decided individually. At the moment, there are no officially approved recommendations for vaccination against SARS-COV‑2 for cancer patients. Before the creation and approval of final recommendations for cancer patients, it is necessary to focus on compliance with sanitary and anti-epidemic measures and the prevention of COVID‑19 infection. The global cancer community continues to actively develop recommendations for the optimal vaccination against SARS-COV‑2 in cancer patients.

The most relevant ones are outlined in this article.

Цель исследования – провести детальный систематический обзор данных мировой литературы, включающий все аспекты, которые отражают рекомендации по вакцинации против SARS-COV‑2 онкологических пациентов.

Материалы и методы. Поиск источников информации выполняли в системах PubMed, MedLine, Scopus, Web of Science, РИНЦ.

В работу включали данные из источников литературы и информации, которые были опубликованы до февраля 2021 г.

Результаты. Проанализированы данные ретроспективных и проспективных клинических исследований. В настоящей работе отражены соображения и рекомендации по вакцинации онкологических больных российскими и зарубежными специалистами в условиях развившейся пандемии COVID‑19. В обзоре представлены современные рекомендации по вакцинации против SARS-COV‑2 больных с солидными опухолями, онкогематологических больных, реципиентов гемопоэтических стволовых клеток и клеточной терапии.

Заключение. На сегодняшний день выделены группы повышенного риска инфицирования новым коронавирусом. К таким группам относятся пациенты с онкологическими заболеваниями. Наличие опухолевого процесса не допускает задержки в проведении терапии, требует тщательного контроля и наблюдения. В связи с этим, несмотря на пандемию, лечение онкологических пациентов необходимо продолжать вне зависимости от обстоятельств.

Онкологические больные не должны быть лишены возможности вакцинироваться против SARS-COV‑2. С каждым больным вопрос должен решаться индивидуально. На данный момент не существует официально утвержденных рекомендаций по проведению вакцинации против SARS-COV‑2 онкологическим пациентам. До создания и утверждения окончательных рекомендаций онкологическим больным необходимо сосредоточить свое внимание на соблюдении санитарно-противоэпидемических мер и профилактике заражения COVID‑19. Мировое онкологическое сообщество продолжает активно разрабатывать рекомендации по оптимальному проведению вакцинации против SARS-COV‑2 онкологических пациентов. Наиболее актуальные из них изложены в данной статье.

vaccinationCOVID-19SARS-COV‑2pandemiconcologycancerimmune responsedrug treatment of tumorschemotherapyoncohematologysolid tumorвакцинацияCOVID‑19SARS-COV‑2пандемияонкологияракиммунный ответлекарственное лечение опухолейхимиотерапияонкогематологиясолидная опухоль1. Rüthrich M.M., Giessen-Jung C., Borgmann S. et al. COVID‑19 in cancer patients: clinical characteristics and outcome-an analysis of the LEOSS registry. Ann Hematol 2021;100(2):383–93. DOI: 10.1007/s00277-020-04328-4.Rüthrich M.M., Giessen-Jung C., Borgmann S. et al. COVID‑19 in cancer patients: clinical characteristics and outcome-an analysis of the LEOSS registry. Ann Hematol 2021;100(2):383–93. DOI: 10.1007/s00277-020-04328-4.2. Williamson E.J., Walker A.J., Bhaskaran K. et al. Factors associated with COVID‑19‑related death using OpenSAFELY. Nature 2020;584(7821):430–6. DOI: 10.1038/s41586-020-2521-4.Williamson E.J., Walker A.J., Bhaskaran K. et al. Factors associated with COVID‑19‑related death using OpenSAFELY. Nature 2020;584(7821):430–6. DOI: 10.1038/s41586-020-2521-4.3. Kuderer N.M., Choueiri T.K., Shah D.P. et al. Clinical impact of COVID‑19 on patients with cancer (CCC19): a cohort study. Lancet 2020;395(10241):1907–18. DOI: 10.1016/S0140-6736(20)31187-9.Kuderer N.M., Choueiri T.K., Shah D.P. et al. Clinical impact of COVID‑19 on patients with cancer (CCC19): a cohort study. Lancet 2020;395(10241):1907–18. DOI: 10.1016/S0140-6736(20)31187-9.4. Martín-Moro F., Marquet J., Piris M. et al. Survival study of hospitalised patients with concurrent COVID‑19 and haematological malignancies. Br J Haematol 2020;190(1):e16–20. DOI: 10.1111/bjh.16801.Martín-Moro F., Marquet J., Piris M. et al. Survival study of hospitalised patients with concurrent COVID‑19 and haematological malignancies. Br J Haematol 2020;190(1):e16–20. DOI: 10.1111/bjh.16801.5. Cordonnier C., Einarsdottir S., Cesaro S. et al. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis 2019;19(6): e200–12. DOI: 10.1016/S1473-3099(18)30600-5.Cordonnier C., Einarsdottir S., Cesaro S. et al. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis 2019;19(6): e200–12. DOI: 10.1016/S1473-3099(18)30600-5.6. Mikulska M., Cesaro S., de Lavallade H. et al. Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference цon Infections in Leukaemia (ECIL 7). Lancet Infect Dis 2019;19(6): e188–99. DOI: 10.1016/S1473-3099(18)30601-7.Mikulska M., Cesaro S., de Lavallade H. et al. Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference цon Infections in Leukaemia (ECIL 7). Lancet Infect Dis 2019;19(6): e188–99. DOI: 10.1016/S1473-3099(18)30601-7.7. Rieger C.T., Liss B., Mellinghoff S. et al. Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Ann Oncol 2018;29(6):1354–65. DOI: 10.1093/annonc/mdy117.Rieger C.T., Liss B., Mellinghoff S. et al. Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors-Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Ann Oncol 2018;29(6):1354–65. DOI: 10.1093/annonc/mdy117.8. Ward E.M., Flowers C.R., Gansler T. et al. The importance of immunization in cancer prevention, treatment, and survivorship. CA Cancer J Clin 2017;67(5):398–410. DOI: 10.3322/caac.21407.Ward E.M., Flowers C.R., Gansler T. et al. The importance of immunization in cancer prevention, treatment, and survivorship. CA Cancer J Clin 2017;67(5):398–410. DOI: 10.3322/caac.21407.9. Rubin L.G., Levin M.J., Ljungman P. et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014;58(3):309–18. DOI: 10.1093/cid/cit816.Rubin L.G., Levin M.J., Ljungman P. et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014;58(3):309–18. DOI: 10.1093/cid/cit816.10. Bitterman R., Eliakim-Raz N., Vinograd I. et al. Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database Syst Rev 2018;2(2): CD008983. DOI: 10.1002/14651858.CD008983.pub3.Bitterman R., Eliakim-Raz N., Vinograd I. et al. Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database Syst Rev 2018;2(2): CD008983. DOI: 10.1002/14651858.CD008983.pub3.11. Anderson H., Petrie K., Berrisford C. et al. Seroconversion after influenza vaccination in patients with lung cancer. Br J Cancer 1999;80(1–2):219–20. DOI: 10.1038/sj.bjc.6690342.Anderson H., Petrie K., Berrisford C. et al. Seroconversion after influenza vaccination in patients with lung cancer. Br J Cancer 1999;80(1–2):219–20. DOI: 10.1038/sj.bjc.6690342.12. Brydak L.B., Guzy J., Starzyk J. et al. Humoral immune response after vaccination against influenza in patients with breast cancer. Support Care Cancer 2001;9(1):65–8. DOI: 10.1007/s005200000186.Brydak L.B., Guzy J., Starzyk J. et al. Humoral immune response after vaccination against influenza in patients with breast cancer. Support Care Cancer 2001;9(1):65–8. DOI: 10.1007/s005200000186.13. Nordøy T., Aaberge I.S., Husebekk A. et al. Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae. Med Oncol 2002;19(2):71–8. DOI: 10.1385/MO:19:2:71.Nordøy T., Aaberge I.S., Husebekk A. et al. Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae. Med Oncol 2002;19(2):71–8. DOI: 10.1385/MO:19:2:71.14. Loulergue P., Alexandre J., Iurisci I. et al. Low immunogenicity of seasonal trivalent influenza vaccine among patients receiving docetaxel for a solid tumour: results of a prospective pilot study. Br J Cancer 2011;104(11):1670–4. DOI: 10.1038/bjc.2011.142.Loulergue P., Alexandre J., Iurisci I. et al. Low immunogenicity of seasonal trivalent influenza vaccine among patients receiving docetaxel for a solid tumour: results of a prospective pilot study. Br J Cancer 2011;104(11):1670–4. DOI: 10.1038/bjc.2011.142.15. Bayle A., Khettab M., Lucibello F. et al. Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD‑1 or PD-L1. Ann Oncol 2020;31(7):959–61. DOI: 10.1016/j.annonc.2020.03.290.Bayle A., Khettab M., Lucibello F. et al. Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD‑1 or PD-L1. Ann Oncol 2020;31(7):959–61. DOI: 10.1016/j.annonc.2020.03.290.16. Rousseau B., Loulergue P., Mir O. et al. Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study. Ann Oncol 012;23(2): 450–7. DOI: 10.1093/annonc/mdr141.Rousseau B., Loulergue P., Mir O. et al. Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study. Ann Oncol 012;23(2): 450–7. DOI: 10.1093/annonc/mdr141.17. Bedognetti D., Ansaldi F., Zanardi E. et al. Seasonal and pandemic (A/ H1N1 2009) MF-59-adjuvanted influenza vaccines in complete remission non-Hodgkin lymphoma patients previously treated with rituximab containing regimens. Blood 2012;120(9):1954–7. DOI: 10.1182/blood-2012-06-438689.Bedognetti D., Ansaldi F., Zanardi E. et al. Seasonal and pandemic (A/ H1N1 2009) MF-59-adjuvanted influenza vaccines in complete remission non-Hodgkin lymphoma patients previously treated with rituximab containing regimens. Blood 2012;120(9):1954–7. DOI: 10.1182/blood-2012-06-438689.18. Bedognetti D., Zoppoli G., Massucco C. et al. Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin’s lymphoma patients treated with rituximab-containing regimens. J Immunol 2011;186(10):6044–55. DOI: 10.4049/jimmunol.1004095.Bedognetti D., Zoppoli G., Massucco C. et al. Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin’s lymphoma patients treated with rituximab-containing regimens. J Immunol 2011;186(10):6044–55. DOI: 10.4049/jimmunol.1004095.19. Berglund A., Willén L., Grödeberg L. et al. The response to vaccination against influenza A(H1N1) 2009, seasonal influenza and Streptococcus pneumoniae in adult outpatients with ongoing treatment for cancer with and without rituximab. Acta Oncol 2014;53(9):1212–20. DOI: 10.3109/0284186X.2014.914243.Berglund A., Willén L., Grödeberg L. et al. The response to vaccination against influenza A(H1N1) 2009, seasonal influenza and Streptococcus pneumoniae in adult outpatients with ongoing treatment for cancer with and without rituximab. Acta Oncol 2014;53(9):1212–20. DOI: 10.3109/0284186X.2014.914243.20. Van Assen S., Holvast A., Benne C.A. et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010;62(1):75–81. DOI: 10.1002/art.25033.Van Assen S., Holvast A., Benne C.A. et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010;62(1):75–81. DOI: 10.1002/art.25033.21. Yri O.E., Torfoss D., Hungnes O. et al. Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood 2011;118:6769–71.Yri O.E., Torfoss D., Hungnes O. et al. Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood 2011;118:6769–71.22. MSK COVID-19 Vaccine Interim Guidelines for Cancer Patients. Available at: https://www.asco.org/sites/new-www.asco.org/files/content-files/covid-19/2021-MSK-COVID19-VACCINEGUIDELINES.pdf.MSK COVID-19 Vaccine Interim Guidelines for Cancer Patients. Available at: https://www.asco.org/sites/new-www.asco.org/files/content-files/covid-19/2021-MSK-COVID19-VACCINEGUIDELINES.pdf.23. Lopez A., Mariette X., Bachelez H. et al. Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis. J Autoimmun 2017;80:10–27. DOI: 10.1016/j.jaut.2017.03.011.Lopez A., Mariette X., Bachelez H. et al. Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis. J Autoimmun 2017;80:10–27. DOI: 10.1016/j.jaut.2017.03.011.24. Fanciullino R., Ciccolini J., Milano G. COVID-19 vaccine race: watch your step for cancer patients. Br J Cancer 2021;124(5):860–61. DOI: 10.1038/s41416-020-01219-3.Fanciullino R., Ciccolini J., Milano G. COVID-19 vaccine race: watch your step for cancer patients. Br J Cancer 2021;124(5):860–61. DOI: 10.1038/s41416-020-01219-3.25. WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination. 14 September 2020. World Health Organization, 2020 (19 December 2020, date last accessed).WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination. 14 September 2020. World Health Organization, 2020 (19 December 2020, date last accessed).26. Evidence to recommendations for COVID-19 vaccines: Evidence framework. World Health Organization, 2020 (19 December 2020, date last accessed).Evidence to recommendations for COVID-19 vaccines: Evidence framework. World Health Organization, 2020 (19 December 2020, date last accessed).27. Dooling K. Phase 1 allocation COVID‑19 vaccine: Work Group considerations. ACIP COVID-19 Vaccines Work Group, 2020 (19 December 2020, date last accessed).Dooling K. Phase 1 allocation COVID‑19 vaccine: Work Group considerations. ACIP COVID-19 Vaccines Work Group, 2020 (19 December 2020, date last accessed).28. Australian Technical Advisory Group on Immunization (ATAGI). Preliminary advice on general principles to guide the prioritisation of target populations in a COVID‑19 vaccination program in Australia (19 December 2020, date last accessed).Australian Technical Advisory Group on Immunization (ATAGI). Preliminary advice on general principles to guide the prioritisation of target populations in a COVID‑19 vaccination program in Australia (19 December 2020, date last accessed).29. Conseil supérieur de la santé. Stratégie de vaccination contre le COVID-19 en Belgique. 2020 (19 December 2020, date last accessed).Conseil supérieur de la santé. Stratégie de vaccination contre le COVID-19 en Belgique. 2020 (19 December 2020, date last accessed).30. Recommandations générales du conseil superieur des maladies infectieuses, concernant la stratégie vaccina lecontre la COVID‑19. Conseil Superieur Des Maladies Infectieuses, 2020 (19 December 2020, date last accessed).Recommandations générales du conseil superieur des maladies infectieuses, concernant la stratégie vaccina lecontre la COVID‑19. Conseil Superieur Des Maladies Infectieuses, 2020 (19 December 2020, date last accessed).31. Nationell plan för vaccination mot COVID-19 (19 December 2020, date last accessed).Nationell plan för vaccination mot COVID-19 (19 December 2020, date last accessed).32. NCCN COVID-19 Vaccination Guidance V1.0, 01/22/2021. The official site of NCCN. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx.NCCN COVID-19 Vaccination Guidance V1.0, 01/22/2021. The official site of NCCN. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx.33. https://www.cdc.gov/vaccines/hcp/aciprecs/general-recs/immunocompetence.html (11 January 2021, date last accessed).https://www.cdc.gov/vaccines/hcp/aciprecs/general-recs/immunocompetence.html (11 January 2021, date last accessed).34. Kamboj M., Shah M.K. Vaccination of the stem cell transplant recipient and the hematologic malignancy patient. Infect Dis Clin North Am 2019;33(2):593–609. DOI: 10.1016/j.idc.2019.02.007.Kamboj M., Shah M.K. Vaccination of the stem cell transplant recipient and the hematologic malignancy patient. Infect Dis Clin North Am 2019;33(2):593–609. DOI: 10.1016/j.idc.2019.02.007.35. https://www.cdc.gov/vaccines/acip/recommendations.html.https://www.cdc.gov/vaccines/acip/recommendations.html.36. American Society of Hematology. Available at: https://www.hematology.org/covid-19/ash-astct-covid-19-andvaccines.American Society of Hematology. Available at: https://www.hematology.org/covid-19/ash-astct-covid-19-andvaccines.37. American Society of Clinical Oncology. Available at: https://www.asco.org/ascocoronavirus-resources/covid-19-vaccinespatients-cancer.American Society of Clinical Oncology. Available at: https://www.asco.org/ascocoronavirus-resources/covid-19-vaccinespatients-cancer.38. RECOVERY Collaborative Group, Horby P., Lim W. S. et al. Dexamethasone in hospitalized patients with COVID-19 – preliminary report. N Engl J Med 2021;384(8):693–704. DOI: 10.1056/NEJMoa2021436.RECOVERY Collaborative Group, Horby P., Lim W. S. et al. Dexamethasone in hospitalized patients with COVID-19 – preliminary report. N Engl J Med 2021;384(8):693–704. DOI: 10.1056/NEJMoa2021436.39. COVID-19 vaccination in cancer patients: ESMO statements. Available at: https:// www.esmo.org/covid-19-and-cancer/covid-19-vaccination.COVID-19 vaccination in cancer patients: ESMO statements. Available at: https:// www.esmo.org/covid-19-and-cancer/covid-19-vaccination.40. https://www.ebmt.org/sites/default/files/2021-02/COVID%20vaccines%20version%205.02%20-%202021-02-21.pdf.https://www.ebmt.org/sites/default/files/2021-02/COVID%20vaccines%20version%205.02%20-%202021-02-21.pdf.41. https://www.hematology.org/covid-19/ash-astct-covid-19-and-vaccines.https://www.hematology.org/covid-19/ash-astct-covid-19-and-vaccines.42. Luo J., Rizvi H., Egger J.V. et al. Impact of PD-1 blockade on COVID-19 severity in patients with lung cancer. Cancer Discov 2020;10(8):1121–8. DOI: 10.1158/2159-8290.CD-20-0596.Luo J., Rizvi H., Egger J.V. et al. Impact of PD-1 blockade on COVID-19 severity in patients with lung cancer. Cancer Discov 2020;10(8):1121–8. DOI: 10.1158/2159-8290.CD-20-0596.43. Garassino M.C., Whisenant J.G., Huang L.C. et al. COVID-19 in patients with thoracic cancer (TERAVOLT): first results from an international registry-based cohort study. Lancet Oncol 2020; 21(7):914–22. DOI: 10.1016/S1470-2045(20)30314-4.Garassino M.C., Whisenant J.G., Huang L.C. et al. COVID-19 in patients with thoracic cancer (TERAVOLT): first results from an international registry-based cohort study. Lancet Oncol 2020; 21(7):914–22. DOI: 10.1016/S1470-2045(20)30314-4.44. Kang S.K., Kim H.R., Song K.H. et al. Cell-mediated immunogenicity of influenza vaccination in cancer patients receiving immune checkpoint inhibitors. J Infect Dis 2020;222(11):1902–9. DOI: 10.1093/infdis/jiaa291.Kang S.K., Kim H.R., Song K.H. et al. Cell-mediated immunogenicity of influenza vaccination in cancer patients receiving immune checkpoint inhibitors. J Infect Dis 2020;222(11):1902–9. DOI: 10.1093/infdis/jiaa291.45. Keam B., Kang S.K., Jun K.I. et al. Immunogenicity of influenza vaccination in cancer patients receiving immune checkpoint inhibitors. Clin Infect Dis 2020;71(2):422–5. DOI: 10.1093/cid/ciz1092.Keam B., Kang S.K., Jun K.I. et al. Immunogenicity of influenza vaccination in cancer patients receiving immune checkpoint inhibitors. Clin Infect Dis 2020;71(2):422–5. DOI: 10.1093/cid/ciz1092.46. Failing J.J., Ho T.P., Yadav S. et al. The safety of influenza vaccine in cancer patients receiving pembrolizumab. JCO Oncol Pract 2020;16(7):e573–80. DOI: 10.1200/JOP.19.00495.Failing J.J., Ho T.P., Yadav S. et al. The safety of influenza vaccine in cancer patients receiving pembrolizumab. JCO Oncol Pract 2020;16(7):e573–80. DOI: 10.1200/JOP.19.00495.47. Chong C.R., Park V.J., Cohen B. et al. Safety of inactivated influenza vaccine in cancer patients receiving immune checkpoint inhibitors. Clin Infect Dis 2020;70(2):193–9. DOI: 10.1093/cid/ciz202.Chong C.R., Park V.J., Cohen B. et al. Safety of inactivated influenza vaccine in cancer patients receiving immune checkpoint inhibitors. Clin Infect Dis 2020;70(2):193–9. DOI: 10.1093/cid/ciz202.48. Wijn D.H., Groeneveld G.H., Vollaard A.M. et al. Influenza vaccination in lung cancer patients receiving immunotherapy against the programmed death receptor 1 does not cause immune-related side effects. Eur J Cancer 2018;104:182–7. DOI: 10.1016/j.ejca.2018.09.012.Wijn D.H., Groeneveld G.H., Vollaard A.M. et al. Influenza vaccination in lung cancer patients receiving immunotherapy against the programmed death receptor 1 does not cause immune-related side effects. Eur J Cancer 2018;104:182–7. DOI: 10.1016/j.ejca.2018.09.012.